MedTrace Logo

Safety on Switching Between Different Botulinum Toxin-A

NCT03234413 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2018-01-08

No results posted yet for this study

Summary

Clinical guidelines recommend the use of Botulinum Toxin-A (BoNT-A) for localized/segmental spasticity in children with cerebral palsy. At the Kocaeli University (KOU) Department of Physical Medicine and Rehabilitation (PMR) more than 800 patients have been injected with the two approved toxinA types; OnabotulinumtoxinA or AbobotulinumtoxinA.

With this study investigators would like to evaluate retrospectively if switching from one toxin to another is safe as well as to evaluate if the efficacy when switching from one toxin to another was maintained.

Conditions

  • Cerebral Palsy

Interventions

DRUG

Botulinum toxin type A

Botulinum toxin type A

Sponsors & Collaborators

  • Nigar Dursun

    lead OTHER

Principal Investigators

  • Nigar Dursun, MD · Kocaeli University

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-30
Primary Completion
2017-11-30
Completion
2017-11-30
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03234413 on ClinicalTrials.gov